Scholarlink

<p>We aimed to identify methamphetamine use patterns and impact by gender/sexual orientation among people with HIV (PWH) in care. We queried 3-month drug use/impact. Women were grouped by gender (cis/trans); cisgender men by sexual orientation. Differences in drug use/impact were assessed using chi-squared and t-tests. We used linear and logistic regression models for each drug use measure, adjusting for age and race/ethnicity. Among 13938 PWH (MA 48), 30% reported ever using methamphetamine; 10% reported current use; 79% were cisgender men (74% men who have sex with men (MSM), 20% men who have sex with women (MSW), 6% men who have sex with men/women (MSMW). Among women (21%), 8% were transgender (TW). TW and MSM reported higher current methamphetamine use (each 14%) than other groups [MSMW (13%), MSW (6%), CW (3%)(<i>p</i> &lt; 0.001)]. Severity of use was highest among TW, compared to MSM (17.8 vs. 14.1, <i>p</i> = 0.04). All groups using methamphetamine were more likely than MSM to currently use cocaine/crack (<i>p</i> = 0.002–0.04); all but TW were more likely than MSM to report illicit opioid use (<i>p</i> &lt; 0.001–0.03). MSM had highest injection use (34% vs. 17–25%, <i>p</i> = 0.05). Related health/legal/financial/social problems were most frequent among TW and MSMW (71%, 55%)]. Persons currently using methamphetamine had lower antiretroviral adherence than those not using (81–85% vs. 91–94%), and higher detectable viral load (28–41% vs. 13–20%). In the adjusted analysis, TW were more likely than MSM to report daily/almost daily use (<i>p</i> = 0.04). Methamphetamine use and impact differ by gender and by cisgender men’s sexual orientation, warranting inquiry into moderating factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differences in Methamphetamine Use, Self-Reported Impact, and HIV-Related Outcomes by Gender and Sexual Orientation in a Multisite U.S. Cohort of People with HIV in Care

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • R.J. Fredericksen,
  • R.M. Nance,
  • L.N. Drumright,
  • L.S. Mixson,
  • S.A. Ruderman,
  • B.M. Whitney,
  • C. Fahey,
  • K.H. Mayer,
  • J.P. Jain,
  • M. Saag,
  • J. Eron,
  • S. Napravnik,
  • L. Bamford,
  • E. Cachay,
  • G.A. Yendewa,
  • J. Keruly,
  • R.D. Moore,
  • A. Rodriguez,
  • S. Safren,
  • J.A.C. Delaney,
  • H.M. Crane,
  • A.W. Hahn

摘要

We aimed to identify methamphetamine use patterns and impact by gender/sexual orientation among people with HIV (PWH) in care. We queried 3-month drug use/impact. Women were grouped by gender (cis/trans); cisgender men by sexual orientation. Differences in drug use/impact were assessed using chi-squared and t-tests. We used linear and logistic regression models for each drug use measure, adjusting for age and race/ethnicity. Among 13938 PWH (MA 48), 30% reported ever using methamphetamine; 10% reported current use; 79% were cisgender men (74% men who have sex with men (MSM), 20% men who have sex with women (MSW), 6% men who have sex with men/women (MSMW). Among women (21%), 8% were transgender (TW). TW and MSM reported higher current methamphetamine use (each 14%) than other groups [MSMW (13%), MSW (6%), CW (3%)(p < 0.001)]. Severity of use was highest among TW, compared to MSM (17.8 vs. 14.1, p = 0.04). All groups using methamphetamine were more likely than MSM to currently use cocaine/crack (p = 0.002–0.04); all but TW were more likely than MSM to report illicit opioid use (p < 0.001–0.03). MSM had highest injection use (34% vs. 17–25%, p = 0.05). Related health/legal/financial/social problems were most frequent among TW and MSMW (71%, 55%)]. Persons currently using methamphetamine had lower antiretroviral adherence than those not using (81–85% vs. 91–94%), and higher detectable viral load (28–41% vs. 13–20%). In the adjusted analysis, TW were more likely than MSM to report daily/almost daily use (p = 0.04). Methamphetamine use and impact differ by gender and by cisgender men’s sexual orientation, warranting inquiry into moderating factors.